CIUP
The 2nd International

Human Gene Therapy
Conference

December 04-06, 2024 | Cité internationale universitaire de Paris, France

Register Brochure Abstract Program

Key Dates of Gene Forum

March 30, 2024

Abstract Submission Commencement

April 10, 2024

Registration Commencement

September 30, 2024

Abstract Submission Deadline

September 30, 2024

Early-bird Registration Deadline

// ABOUT CONFERENCE

The 2nd International Human Gene Therapy Conference

Conference Chair

Mitra Tavakkoli
Mitra Tavakkoli

Clinical Development Physician and Senior Biotech Consultant, USA

We are thrilled and overwhelmed to announce the Gene Forum 2024 the sequel to the highly successful Gene Forum 2022 conference. This international summit, set against the backdrop of Paris, France, marks our commitment to pushing the boundaries of gene therapy. A cordial invitation is extended to you as we embark on this transformative journey. Gene Forum 2024 is a meticulously curated event designed to illuminate the panorama of gene therapy, not just in Europe but on a global scale. Our objective is to cultivate collaboration among pivotal figures in gene therapy—bringing together , Industry spearheads, and Collaborators. The conference aspires to unite influential figures in the gene therapy sector.
It provides an invaluable platform for exchanging innovative fresh findings and trends in gene therapy—a field poised to revolutionize healthcare by addressing genetic disorders and advancing personalized medicine. Gene Forum is uniquely tailored to deliver actionable insights, expert guidance, peer networking, and assessments from solution providers. The experience promises to be unforgettable and transformative, empowering you and your organization to achieve heightened performance in addressing critical priorities, offering a chance to showcase innovations and connect with industry leaders. We believe in the power of collaboration, and the success of Gene Forum 2022 showcased the importance of active participation. Regardless of where you stand in the gene therapy value chain, your voice matters, and we invite you to join us at Gene Forum 2024. The significance of gene therapy in revolutionizing medical care and addressing genetic challenges cannot be overstated. Gene therapy stands at the forefront of medical innovation, and its impact resonates globally. Despite the challenges, the imperative for breakthroughs in treating genetic conditions necessitates collaboration, shared knowledge, and a collective effort. Gene Forum 2024 provides a platform to explore the latest advancements, engage in discussions, and share ideas. The summit will host thought-provoking sessions to create an environment conducive to meaningful interactions and collaborations. Secure your place early at Gene Forum 2024, where we anticipate a surge in interest. Register now to be part of this premier interdisciplinary platform for Industrialists, Researchers, Practitioners, and Educators shaping the future of gene therapy.

Read More

Featured Speakers

Anne Douar
Anne Douar

Chief Operating Officer, Vivet Therapeutics, France

Binh Nguyen
Binh Nguyen

President, WYNNGATE Corporation, EX-FDA, USA

Cellia Habita
Cellia Habita

Biotech Senior Executive, Expert in Drug Development & Clinical Development Operations, France

James L Drinkwater
James L Drinkwater

Ex-Chairman Honorary Member of PHSS, Head of GMP Compliance, Franz Ziel GmbH, United Kingdom

Jeff Chaffin
Jeff Chaffin

Principal
Miles Payer Consulting, USA

Larry Forman
Larry Forman

Founder & CEO
CHO Plus, USA

Mitra Tavakkoli
Mitra Tavakkoli

Clinical Development Physician and Senior Biotech Consultant, USA

Natasha Paterson
Natasha Paterson

Executive Director Medical Affairs, Tenaya Therapeutics, USA

Olivier Negre
Olivier Negre

Chief Scientific Officer, Smart Immune, France

Sophie Blondel
Sophie Blondel

Consultant and Cell and Gene Therapies Expert, France

Tristan Jervis
Tristan Jervis

Founder and Managing Director, Impact Shine Communications, UK

view more
// SCIENTIFIC SESSION

Key Topics

  • Gene Therapy Development and Methods
  • Gene Drug Delivery and Recent Gene Editing Technologies
  • Benefits, Risks and Applications of Gene Therapy
  • Gene Therapy Clinical Trials and Regulatory Landscape
  • Safety, Efficacy, Risk Management and Pharmacovigilance in CGT
  • Ethical and Societal Considerations
  • Worldwide Approved and Successfully Running CGTs
  • Patient Engagement
  • Gene Therapy R&D Acceleration by AI
  • Gene Therapy Successes and Ongoing Research
  • Analytical Process Development and Scale-Up Technologies
  • Quality Assurance and Quality Control
  • GLP, GMP Compliances
  • Personalized Medicines
  • Market Analysis, Trends and Opportunities
  • Logistics, Supply Chain, Cost Optimization and Affordability
  • Pricing Strategies, Market access, Commercialization and Reimbursement IPR's and Licensing
  • Investments, Partnerships and Fundings on Global Scale
  • Success Stories from Research Lab to Market
  • CGT Approaches for Cancer Treatment
  • Combination of Gene and Cellular Immunotherapies
  • DNA & RNA based Technologies
  • CGT Approaches for HIV-AIDS, Pulmonary Disorders, Sickle Cell Anaemia, Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency, Haemophilia, Beta thalassemia, Diabetes
  • Gene therapy for Ophthalmic and Muscular Disorders
  • Gene Therapy for Neurodegenerative and Rare disorders
  • Bio Revolution Uniting 3D Bioprinting and Gene Therapy for Tomorrow's Healthcare
  • Emerging Therapies for Genetic Disorders
  • Navigating Next by NGS Technology

Gene Forum Market in Europe

The gene therapy market in Europe is experiencing notable growth, driven by increased research, development, and commercialization activities. Gene therapy, involving the modification of genetic material to treat or prevent diseases, has gained traction in Europe due to technological advancements, a supportive regulatory environment, and rising investments. Europe's gene therapy market benefits from a robust regulatory framework that encourages innovation and expedites the approval process. Regulatory bodies, including the European Medicines Agency (EMA), have adapted guidelines to address the unique challenges of gene therapies, fostering an environment conducive to clinical trials and market introduction. Investment and funding in the gene therapy sector have seen a significant uptick, with both public and private sectors recognizing the therapeutic potential of these innovative approaches. Collaborations between industry players, academic institutions, and research organizations have intensified, creating a synergistic ecosystem that accelerates the development of novel gene therapies. Technological advancements, especially in gene editing technologies like CRISPR-Cas9, have played a crucial role in shaping the gene therapy landscape in Europe. Researchers and companies are exploring innovative vector designs, delivery systems, and manufacturing processes to enhance the precision, efficiency, and scalability of gene therapies. The market is witnessing increased activity across various therapeutic areas, including rare genetic disorders, oncology, and neurodegenerative diseases. As gene therapies progress from research and development to commercialization, considerations such as market access, pricing, and reimbursement strategies have become critical for stakeholders in Europe’s healthcare landscape. The Europe gene therapy market is segmented into four notable segments based on vector type, method, application, and end user. Germany is dominating due to the presence of key market players in the largest consumer market with a high GDP. The U.S. is expected to grow due to the rise in technological advancement in the gene therapy products market. The European gene therapy market is projected to grow at a CAGR of 17.6% during the forecast period by 2030 and the future market value is expected to reach USD 7,422.28 million by 2030.

Why Attend the Gene Therapy Conference

  • Stay Informed on the Latest Research works and happenings on Gene Therapy
  • Meet Experts and Key Opinion Leaders
  • Exposure to Diverse Perspectives of Gene Therapy
  • Access to Industry Exhibits and Technologies
  • QARA Challenges and Solutions
  • Ethical Considerations and Challenges
  • Investments, Partnerships, and Fundings on a Global Scale
  • Global Collaboration and Policy Engagement
  • Networking Opportunities
  • Professional Development
  • Career and Business Opportunities

Who will Attend Gene Forum Conference?

Department

  • Manufacturing
  • Product Development
  • Quality
  • Value & Market Access
  • Therapy Administration
  • Research & Development
  • Regulatory Affairs
  • Vector Systems
  • Engineering
  • Laboratory
  • Science
  • Information Technology
  • Validation
  • Training
  • Clinical
  • Patient Advocacy

Job Function

  • Scientist
  • Executive and Mid-Level Management
  • Project Management
  • Technical Services
  • Supply Chain
  • Manufacturing
  • Application
  • Risk Management
  • Patient Monitoring
  • Customer Engagement
  • Marketing and Sales
  • Clinical Strategy Pharmacist
  • Product Communications
  • Clinical Research
  • Post Doc, PhD Student
// Programs

Program Schedule

Day-1




For regular updates bookmark gene therapy conferences website

Conference Secretariat:
Prism Scientific Services Pty Ltd [PCO]
302/480 Collins Street, Melbourne
VIC 3000, Australia

Phone: +61390163202

Email: deekshitha.g@genetherapyconference.com

Website: https://genetherapyconference.com/

Follow Us :

Quick Links

Subscribe!

We'll never share your email with anyone else.

© - Gene Therapy Conferences Website all rights reserved.